ImmunityBio, Inc. (IBRX) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts IBRX Hot Sheet
Join SI Premium – FREE
ImmunityBio, Inc. (NASDAQ: IBRX) reported Q2 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $26.43 million versus the consensus estimate of $21.49 million.
For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ashland (ASH) Tops Q3 EPS by 2c; offers guidance
- FirstEnergy (FE) Reports In-Line Q2 EPS, Beats on Revenue; Offers FY26 EPS Guidance
- Mirant Corporation (MIR) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
